These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10949)

  • 1. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of beta-, alpha- and combined beta- plus alpha-adrenoceptor blocking agents in stress-induced increase in arterial blood pressure.
    Pandhi P; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):297-300. PubMed ID: 2887519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.
    Sanders GL; Murray A; Rawlins MD
    Br J Clin Pharmacol; 1979; 8(Suppl 2):125S-127S. PubMed ID: 43163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beta-adrenoceptor subtype(s) mediating adrenaline- and dobutamine-induced blood pressure and heart rate changes in healthy volunteers.
    Daul A; Hermes U; Schäfers RF; Wenzel R; von Birgelen C; Brodde OE
    Int J Clin Pharmacol Ther; 1995 Mar; 33(3):140-8. PubMed ID: 7599912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
    Riddell JG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1985 Apr; 19(4):405-10. PubMed ID: 2859871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of labetalol as a moderate hypotensive agent in otological operations--plasma concentrations after intravenous administration.
    Kanto J; Pakkanen A; Allonen H; Kleimola T; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):191-4. PubMed ID: 7390669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):795-8. PubMed ID: 10953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of labetalol on plasma catecholamines at rest and during increased sympathetic activity.
    Carlsen JE; Trap-Jensen J; Svendsen TL; Nielsen PE; Rasmussen S; Christensen NJ
    Postgrad Med J; 1980; 56 Suppl 2():43-8. PubMed ID: 7433342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol.
    Tomlinson B; Cronin CJ; Graham BR; Prichard BN
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S69-75. PubMed ID: 2454372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
    Richards DA; Tuckman J; Prichard BN
    Br J Clin Pharmacol; 1976 Oct; 3(5):849-55. PubMed ID: 9968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.
    Trust PM; Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):799-803. PubMed ID: 791333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between plasma concentrations and pharmacological effects of labetalol.
    Richards DA; Maconochie JG; Bland RE; Hopkins R; Woodings EP; Martin LE
    Eur J Clin Pharmacol; 1977 Jan; 11(2):85-90. PubMed ID: 14010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure lowering action and alpha-adrenolytic effect of adimolol in rats.
    Palluk R; Hoefke W
    Arch Int Pharmacodyn Ther; 1989; 301():215-27. PubMed ID: 2576194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.